Dexamethasone Polymer Suspension for Blepharitis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for blepharitis, which often involve broad-spectrum antibiotics, face challenges such as drug resistance and undesirable side effects, necessitating a more effective and safer therapeutic approach.
Innovation Solution
A method involving the administration of a glucocorticoid, such as dexamethasone, in an ophthalmically acceptable vehicle with a carboxyl-containing polymer suspension that provides sustained release, reducing the reliance on antibiotics and addressing the inflammation associated with blepharitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad-spectrum antibiotics are used to treat blepharitis, then bacterial infection is controlled, but drug resistance develops and side effects increase
Solution Approach 1:
The patent changes the active ingredient from antibiotic to glucocorticoid, fundamentally altering the treatment mechanism from antibacterial to anti-inflammatory. This parameter change eliminates the problem of antibiotic resistance while maintaining treatment effectiveness for inflammatory conditions
Solution Approach 2:
The patent extracts and removes the antibiotic component from the treatment regimen, relying solely on glucocorticoid therapy. This extraction eliminates the harmful effects associated with antibiotic overuse while preserving the ability to treat the inflammatory aspect of blepharitis
2Reliability
If glucocorticoid is administered with sustained release polymer suspension, then treatment effectiveness is improved, but formulation complexity increases
Solution Approach 1:
The patent introduces a carboxyl-containing polymer suspension as an intermediary delivery system. This mediator provides sustained release of glucocorticoid, improving treatment effectiveness while the polymer itself is a well-established ophthalmic vehicle that doesn't significantly increase overall formulation complexity
Solution Approach 2:
The patent modifies the physical parameters of the formulation by using a polymer suspension system with specific viscosity ranges (1,000-30,000 centipoises) and cross-linking percentages (less than 5% by weight). These controlled parameter changes enable sustained release while maintaining manufacturability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively ameliorates clinical signs and symptoms of blepharitis while minimizing the risk of drug resistance and side effects, offering a safer and more sustainable treatment option.
Implementation Method 1
The vehicle includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of the active ingredient
Implementation Method 2
The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises
Data Source
AI summary
A method of treating blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.